Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
12.44 USD -0.36 ( 2.81%)
Last update at 2026-11-06T21:00:00Z
VOLUME
15710
Market Cap
0.56M

Momentum Score

…

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. is based in Arlington, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
12.40
Low
12.88
High
52 Week Price Range
-
Low
0.25
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Eloxx Pharmaceuticals is a clinical-stage biopharma developing small molecules to promote read-through of premature stop codons in rare genetic diseases caused by nonsense mutations. Growth may be driven by clinical readouts, regulatory approvals, indication expansion, and partnerships. It could appeal to investors by addressing clear unmet needs with biomarker-driven programs.

Principal risks include failure in pivotal trials or regulatory review, limited cash runway and dilution risk, competition from gene therapies and alternative approaches, and recruitment challenges in rare-disease studies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
12.80
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.08
ROE
-615.23%
Net Debt
-3.79M
ROCE
56.13%
Diluted EPS TTM
-0.49

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.00M -3.14M -17.05M -36.06M -66.73M
Net income -6.00M -3.14M -17.05M -36.11M -65.77M
Selling general administrative 3.38M 5.25M 8.69M 10.69M 20.45M
Reconciled depreciation 0.00M 0.16M 0.81M 0.69M 0.96M
Ebit -6.68M - - -35.11M -66.98M
Ebitda -6.44M - - -34.42M -66.02M
Depreciation and amortization 0.24M - - 0.69M 0.96M
Operating income -6.44M -2.47M -17.29M -34.42M -66.02M
Other operating expenses 6.44M - - 34.42M 66.02M
Interest expense 1.05M 1.14M 1.15M 1.95M 1.26M
Interest income 0.03M 0.03M 0.25M 0.27M 0.01M
Net interest income -0.86M -1.12M -0.90M -1.68M -1.25M
Income tax expense - - - 0.05M -0.96M
Total revenue 0.00M 6.36M 0.00M 0.00M 0.00M
Total operating expenses 6.44M 8.83M 17.29M 34.42M 66.02M
Total other income expense net 0.44M 0.44M 1.13M -1.65M -0.71M
Net income from continuing ops -6.00M -3.14M -17.05M -36.06M -66.73M
Net income applicable to common shares - - - - -66.73M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5.27M 2.98M 1.71M 21.12M 45.14M
Other current assets 0.48M 0.14M 0.19M 0.66M 1.21M
Total liab 17.18M 27.31M 24.31M 31.78M 22.75M
Total stockholder equity -11.91M -24.34M -22.60M -10.66M 22.38M
Other current liab 13.46M 0.10M 0.47M 2.84M 4.20M
Common stock 0.05M - - 0.02M 0.87M
Capital stock 0.05M 0.04M 0.03M 0.02M 0.87M
Retained earnings -300.58M -294.58M -291.44M -274.39M -238.32M
Cash 4.79M 0.11M 1.13M 19.21M 42.27M
Total current liabilities 17.18M 27.31M 22.70M 23.09M 9.96M
Current deferred revenue - - - 12.54M 3.72M
Net debt -3.79M 6.41M 2.70M -5.82M -28.81M
Short term debt 1.00M - - 4.69M 0.66M
Short long term debt 1.00M 6.52M 2.22M 3.98M -
Short long term debt total 1.00M - - 13.38M 13.46M
Other stockholder equity 288.62M - - 263.71M 259.84M
Property plant equipment - - - - 1.66M
Total current assets 5.27M 2.98M 1.55M 20.13M 43.48M
Net tangible assets - - - -10.66M 22.38M
Net receivables 0.00M 2.36M 0.00M - -
Long term debt - - 1.61M 8.56M 12.00M
Accounts payable 2.71M 5.35M 5.70M 3.02M 1.38M
Non current assets total 0.00M 0.00M 0.16M 0.99M 1.66M
Capital lease obligations 0.00M 0.00M 0.14M 0.85M 1.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - 0.26M -0.07M 2.06M
Change to liabilities - - - 0.00M -0.32M
Total cashflows from investing activities 0.00M - - - 2.06M
Net borrowings 1.61M 3.06M -9.40M - 0.49M
Total cash from financing activities 11.00M 3.44M -4.08M 8.81M 50.79M
Change to operating activities - - - - -0.71M
Net income -6.00M -3.14M -17.05M -36.06M -66.73M
Change in cash 4.67M -1.24M -18.11M -23.10M 17.84M
Begin period cash flow 0.12M 1.35M 19.47M 42.57M 24.72M
End period cash flow 4.79M 0.12M 1.35M 19.47M 42.57M
Total cash from operating activities -6.33M -4.71M -14.34M -31.84M -35.00M
Issuance of capital stock 0.00M 0.00M 4.89M 0.00M 47.72M
Depreciation 0.24M 0.16M 0.81M 0.69M 0.96M
Other cashflows from investing activities 0.00M - - - -
Change to account receivables 2.36M -2.36M 0.00M - -
Other cashflows from financing activities 9.39M - - 8.81M 14.45M
Change to netincome - - - - 31.38M
Capital expenditures 0.00M 0.00M 0.00M 0.07M 0.09M
Change in working capital 0.52M -2.36M 0.84M -0.12M -0.03M
Stock based compensation 0.23M 0.54M 1.97M 3.02M 9.17M
Other non cash items -1.33M 0.47M 0.49M 0.62M 22.09M
Free cash flow -6.33M -4.71M -14.34M -31.91M -35.09M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ELOX
Eloxx Pharmaceuticals, Inc.		 -0.36
2.81%		 12.44 - - - 62.37 0.10
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. is based in Arlington, Massachusetts.

10 Court Street, Arlington, MA, United States, 02476

781 577 5300

https://www.eloxxpharma.com

10

Name Title Year Born
Mr. Sumit Aggarwal M.B.A. Pres, CEO & Director 1973
Mr. Daniel E. Geffken M.B.A., MBA Interim CFO, Principal Financial Officer & Principal Accounting Officer 1957
Dr. Vijay Modur MBBS, Ph.D. Head of R&D 1968
Ms. Barbara Ryan Investor Relations Officer NA
Dr. Ali Hariri M.D. Chief Medical Officer NA
Mr. Matthew Goddeeris Ph.D. VP of Research NA
Mr. Sumit Aggarwal M.B.A. President, CEO & Director 1973
Mr. Daniel E. Geffken M.B.A. Interim CFO, Principal Financial Officer & Principal Accounting Officer 1957
Ms. Barbara A. Ryan Investor Relations Officer 1960

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…